✅️ HammerTime ✅️ 1. Cash Flow Positive ✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products. ✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched ✅️ 4. Adderall XR $865 Million IMS market Approved and Launched ✅️ 5. Double digit quarterly revenues in millions ✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams ✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance ✅️ 8. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million ✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023 ✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023k ✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024 __12. Obtain Full ownership of Adderall IR $ 421.7 Million from MIKAH __13. Obtain Full ownership of Adderall XR $ 865 Million from MIKAH ✅️ 14. Generic Methotrexate Antimetabolite- Approval ✅️ 15. Launch generic Methotrexate $63 Million ✅️ 16. $50+ million in yearly revenues ✅️ 17. Lowest PE ratio for OTC Healthcare sector ✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable ✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation ✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research ✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd. ✅️ 22. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024 ✅️ 23. Final Approval of New Manufacturing Facility/Expansion ✅️24. Generate revenues over $20 million/quarter ✅️25. Generate revenues over $30 million/quarter __ 26. Generate revenues over $40 million/quarter —-Imminent __ 27. Generate revenues over $50 million/quarter __ 28. Double output of manufacturing and packaging facilities —-Imminent ✅️ 29. Launch approved generic Tylenol with Codeine $47 Million ✅️ 30. Launch approved generic Norco - hydrocodone acetaminophen IMS $300 Million ✅️ 31. Launch approved generic Percocet - oxycodone acetaminophen IMS $317 Million __ 32. Launch approved generic Dolophine - Methadone HCL tablets IMS $30 Million __ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million ✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion __ 35. Indian Research and Development agreement __ 36. Positive BE Study for Concerta CNS Stimulant $1.16 Billion ✅️ ✅️ ✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024 __38. Generic Concerta- FDA submission $1.16 Billion __39. Launch Adderall IR in Israel —Imminent __40. 100 million in yearly revenues —-2025 calendar __41. Generic OxyContin FDA Approval $720 Million ✅️ 42. Accord Pharma prevail over Purdue in Generic OxyContin infringement suit - Dec 30, 2024 now at Supreme Court https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf __43. Elite prevail over Purdue in Generic OxyContin infringement suit. https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al __43. Launch generic OxyContin $720 Million __44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone this was Drug C in SequestOx reformulation trial __45. Partner for SequestOx Abuse Deterrent Oxycodone __46. $200 million in yearly revenue __47. Undisclosed Mikah ANDA(s) ✅️48. Positive Pivotal BE Undisclosed ANDA JUNE 2025 $27 Billion Market - anticoagulant __49. Generic Concerta Launch $1.16 Billion __50. DollarLand SP——2025 calendar $$$$$$$$$$$$$$ __51. Uplist to NASDAQ exchange __52. M&A advisory firm selected for buyout __53. Perform Business Valuation __54. Buyout offer/s __55. Buyer Identified __56. Buyout Vote of Board of Directors __57. Halt Trading __58. Shareholder vote on offer __59. Buyout Closing Completed —$$$$$$$$$$$ __60. Vegas BABY !!!!! 🎰
Market Data 
Markets 
AI
